Language: BG BG
nav.cta
← Back to results
Recruiting Phase 2 2025-523260-20-00

Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes – a dose-finding study

Phase 2 – studying effectiveness and dosage
Conditions: type 2 diabetes

Sponsor: Novo Nordisk A/S

trial.available_in: БГ
Overview
Trial status: Authorised Relative change in body weight, Change in body weight Change in HbA1c
Description
Relative change in body weight, Change in body weight
Who can participate
Age group: 18-64 years Gender: Female, Male Target enrollment: 90 participants
Interventions
Placebo A
Drug
Semaglutide B Placebo
Drug
Ozempic 0.5 mg solution for injection in pre-filled pen
Drug
Locations 4
Hungary (1)
Poland (1)
Portugal (1)
Slovakia (1)
Technical details
Status
Recruiting
Phase
Phase 2
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Maximum age
64 Years
Healthy volunteers
No
Start date
21.04.2026
Registry ID
2025-523260-20-00
Source
euclinicaltrials.eu
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.